参考文献/References:
[1] Roschewski M, Staudt L M, Wilson W H.Diffuse large B-cell lymphoma-treatment approaches in the molecular era[J].Nat Rev Clin Oncol, 2014, 11(1): 12-23.[2] Polyatskin I L, Artemyeva A S, Krivolapov Y A.Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017(4th edition): lymphoid tumors[J].Arkh Patol, 2019, 81(3):59-65.[3] 马亚辉, 杨琪, 朱洪波, 等.C反应蛋白与前白蛋白比值在评估胃癌病人预后中的临床价值[J].蚌埠医学院学报, 2021, 46(2): 214-217, 221.[4] 谢锦华, 吉浩明, 陈国栋,等.小细胞肺癌患者血清铁蛋白、红细胞沉降率和红细胞平均指数水平与预后的关系[J].国际肿瘤学杂志,2018, 45(8): 465-469.[5] 邵春青,吕虹,刘志伟,等.原发中枢神经系统弥漫性大B细胞淋巴瘤患者血清细胞因子白细胞介素6、白细胞介素8、白细胞介素2受体和肿瘤坏死因子α的水平及临床价值[J].中国临床医生杂志, 2017, 45(8): 57-59.[6] 杨艳.弥漫性大B细胞淋巴瘤中hENT1、NF-κB的表达及意义[D].安徽:安徽医科大学, 2013.[7] 孟伟.TNF-α、TNF-β和PKC-β Ⅱ在弥漫性大B细胞淋巴瘤中的表达及其意义[D].新疆: 新疆医科大学, 2010.[8] 解金洪, 章匀, 唐艳芬.血沉和血清促红细胞生成素评估老年慢性阻塞性肺疾病病情和预后的价值[J].中华保健医学杂志, 2020, 22(6): 638-639, 646.[9] 于洋, 韩春生, 韩桂玲, 等.特发性肺纤维化患者相关预后影响因素的临床研究[J].世界中医药, 2014, 9(8): 978-982.[10] Liu S, Ren J, Xia Q, et al.Preliminary case-control study to evaluate diagnostic values of C-reactive protein and erythrocyte sedimentation rate in differentiating active Crohn's disease from intestinal lymphoma, intestinal tuberculosis and Behcet's syndrome[J].Am J Med Sci, 2013, 346(6): 467-472.[11] Wu S, Zhou Y, Hua H Y, et al.Inflammation marker ESR is effective in predicting outcome of diffuse large B-cell lymphoma[J].BMC Cancer, 2018, 18(1): 997.[12] Rotaru I, Gaman G D, Stanescu C, et al.Evaluation of parameters with potential prognosis impact in patients with primary gastric diffuse large B cell lymphoma(PG-DLBCL)[J].Rom J Morphol Embryol, 2014, 55(1): 15-21.